Irhythm Technologies (0A7L) Share Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0A7L Analyst Ratings

Strong Buy

12 Buy

0 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Irhythm

Technologies

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0A7L Stock 12 Month Forecast

Average Price Target

$174.78

▲(55.51% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Irhythm Technologies in the last 3 months. The average price target is $174.78 with a high forecast of $196.00 and a low forecast of $157.00. The average price target represents a 55.51% change from the last price of $112.39.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"109":"$109","131":"$131","153":"$153","175":"$175","197":"$197"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":196,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$196.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":174.77777777777777,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$174.78</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":157,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$157.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[109,131,153,175,197],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,119.26,125.16307692307693,131.06615384615384,136.96923076923076,142.8723076923077,148.7753846153846,154.67846153846153,160.58153846153846,166.48461538461538,172.3876923076923,178.29076923076923,184.19384615384615,190.09692307692308,{"y":196,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,119.26,123.53059829059829,127.80119658119659,132.07179487179488,136.34239316239317,140.61299145299145,144.88358974358974,149.15418803418802,153.42478632478634,157.69538461538463,161.9659829059829,166.2365811965812,170.50717948717949,{"y":174.77777777777777,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,119.26,122.16307692307693,125.06615384615385,127.96923076923078,130.8723076923077,133.7753846153846,136.67846153846153,139.58153846153846,142.48461538461538,145.3876923076923,148.29076923076923,151.19384615384615,154.09692307692308,{"y":157,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":165.999,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":161.915,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":188.4,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.23,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":178.14,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":157.375,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.56,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.89,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.32,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.17,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.75,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.26,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$196.00

Average Price Target$174.78

Lowest Price Target$157.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

William Plovanic

Canaccord Genuity

$212→$196

Buy

74.39%

Upside

Reiterated

08/27/26

Canaccord Genuity Remains a Buy on Irhythm Technologies (IRTC)

Richard Newitter

Truist Financial

―

Buy

―

Reiterated

08/19/26

Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (NYSE: DGX) and Irhythm Technologies (NASDAQ: IRTC)

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

08/19/26

Analysts Offer Insights on Healthcare Companies: Innovative Eyewear, Inc. (NASDAQ: LUCY) and Irhythm Technologies (NASDAQ: IRTC)

Nathan Treybeck

Wells Fargo

$180→$168

Buy

49.48%

Upside

Assigned

08/18/26

Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (NASDAQ: IRTC) and Heron Therapeutics (NASDAQ: HRTX)

Stephanie Elghazi

Bank of America Securities

―

Buy

―

Reiterated

08/14/26

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (NASDAQ: FDMT), Alto Neuroscience, Inc. (NYSE: ANRO) and Irhythm Technologies (NASDAQ: IRTC)

Joanne Wuensch

Citi

$157

Buy

39.69%

Upside

Reiterated

08/13/26

Citi Sticks to Their Buy Rating for Irhythm Technologies (IRTC)

Suraj Kalia

Oppenheimer

$185

Buy

64.61%

Upside

Assigned

08/10/26

Oppenheimer Reaffirms Their Buy Rating on Irhythm Technologies (IRTC)

Vijay Kumar

Evercore ISI

$150→$165

Buy

46.81%

Upside

Reiterated

08/07/26

iRhythm price target raised to $165 from $150 at Evercore ISIiRhythm price target raised to $165 from $150 at Evercore ISI

David Rescott

Robert W. Baird

$160→$165

Buy

46.81%

Upside

Reiterated

08/07/26

iRhythm price target raised to $165 from $160 at BairdiRhythm price target raised to $165 from $160 at Baird

David Saxon

Needham

$255→$192

Buy

70.83%

Upside

Reiterated

08/07/26

Needham Remains a Buy on Irhythm Technologies (IRTC)

Marie Thibault

BTIG

$185

Buy

64.61%

Upside

Reiterated

08/07/26

Analysts Are Bullish on These Healthcare Stocks: GoodRx Holdings (GDRX), Irhythm Technologies (IRTC)

Mason Carrico

Stephens

$160

Buy

42.36%

Upside

Initiated

07/22/26

iRhythm initiated with an Overweight at StephensiRhythm initiated with an Overweight at Stephens

Allen Gong

J.P. Morgan

$215→$175

Buy

55.71%

Upside

Reiterated

05/01/26

Analysts Conflicted on These Healthcare Names: Irhythm Technologies (NASDAQ: IRTC), Alnylam Pharma (NASDAQ: ALNY) and Avantor (NYSE: AVTR)

David Roman

Goldman Sachs

$147

Hold

30.79%

Upside

Reiterated

04/30/26

Goldman Sachs Sticks to Their Hold Rating for Irhythm Technologies (IRTC)

Patrick Wood

UBS

$195→$205

Buy

82.40%

Upside

Reiterated

12/02/25

iRhythm price target raised to $205 from $195 at Morgan StanleyiRhythm price target raised to $205 from $195 at Morgan Stanley

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

William Plovanic

Canaccord Genuity

$212→$196

Buy

74.39%

Upside

Reiterated

08/27/26

Canaccord Genuity Remains a Buy on Irhythm Technologies (IRTC)

Richard Newitter

Truist Financial

―

Buy

―

Reiterated

08/19/26

Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (NYSE: DGX) and Irhythm Technologies (NASDAQ: IRTC)

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

08/19/26

Analysts Offer Insights on Healthcare Companies: Innovative Eyewear, Inc. (NASDAQ: LUCY) and Irhythm Technologies (NASDAQ: IRTC)

Nathan Treybeck

Wells Fargo

$180→$168

Buy

49.48%

Upside

Assigned

08/18/26

Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (NASDAQ: IRTC) and Heron Therapeutics (NASDAQ: HRTX)

Stephanie Elghazi

Bank of America Securities

―

Buy

―

Reiterated

08/14/26

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (NASDAQ: FDMT), Alto Neuroscience, Inc. (NYSE: ANRO) and Irhythm Technologies (NASDAQ: IRTC)

Joanne Wuensch

Citi

$157

Buy

39.69%

Upside

Reiterated

08/13/26

Citi Sticks to Their Buy Rating for Irhythm Technologies (IRTC)

Suraj Kalia

Oppenheimer

$185

Buy

64.61%

Upside

Assigned

08/10/26

Oppenheimer Reaffirms Their Buy Rating on Irhythm Technologies (IRTC)

Vijay Kumar

Evercore ISI

$150→$165

Buy

46.81%

Upside

Reiterated

08/07/26

iRhythm price target raised to $165 from $150 at Evercore ISIiRhythm price target raised to $165 from $150 at Evercore ISI

David Rescott

Robert W. Baird

$160→$165

Buy

46.81%

Upside

Reiterated

08/07/26

iRhythm price target raised to $165 from $160 at BairdiRhythm price target raised to $165 from $160 at Baird

David Saxon

Needham

$255→$192

Buy

70.83%

Upside

Reiterated

08/07/26

Needham Remains a Buy on Irhythm Technologies (IRTC)

Marie Thibault

BTIG

$185

Buy

64.61%

Upside

Reiterated

08/07/26

Analysts Are Bullish on These Healthcare Stocks: GoodRx Holdings (GDRX), Irhythm Technologies (IRTC)

Mason Carrico

Stephens

$160

Buy

42.36%

Upside

Initiated

07/22/26

iRhythm initiated with an Overweight at StephensiRhythm initiated with an Overweight at Stephens

Allen Gong

J.P. Morgan

$215→$175

Buy

55.71%

Upside

Reiterated

05/01/26

Analysts Conflicted on These Healthcare Names: Irhythm Technologies (NASDAQ: IRTC), Alnylam Pharma (NASDAQ: ALNY) and Avantor (NYSE: AVTR)

David Roman

Goldman Sachs

$147

Hold

30.79%

Upside

Reiterated

04/30/26

Goldman Sachs Sticks to Their Hold Rating for Irhythm Technologies (IRTC)

Patrick Wood

UBS

$195→$205

Buy

82.40%

Upside

Reiterated

12/02/25

iRhythm price target raised to $205 from $195 at Morgan StanleyiRhythm price target raised to $205 from $195 at Morgan Stanley

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

BLTEBelite Bio, Inc. ADR

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Irhythm Technologies

3 Months

David RescottRobert W. Baird

Success Rate

16/28 ratings generated profit

Average Return

+5.85%

Copying David Rescott's trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +5.85% per trade.

1 Year

Richard NewitterTruist Financial

Success Rate

11/27 ratings generated profit

Average Return

+16.51%

Copying Richard Newitter's trades and holding each position for 1 Year would result in 40.74% of your transactions generating a profit, with an average return of +16.51% per trade.

2 Years

Richard NewitterTruist Financial

Success Rate

17/27 ratings generated profit

Average Return

+21.90%

Copying Richard Newitter's trades and holding each position for 2 Years would result in 62.96% of your transactions generating a profit, with an average return of +21.90% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0A7L Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0A7L has received 29 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0A7L average Analyst price target in the past 3 months is 174.78.

Each month's total comprises the sum of three months' worth of ratings.

0A7L Financial Forecast

0A7L Earnings Forecast

Next quarter’s earnings estimate for 0A7L is $0.02 with a range of -$0.16 to $0.27. The previous quarter’s EPS was -$0.01. 0A7L beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0A7L has Performed in-line its overall industry.

0A7L Sales Forecast

Next quarter’s sales forecast for 0A7L is $222.45M with a range of $221.77M to $225.00M. The previous quarter’s sales results were $224.17M. 0A7L beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0A7L has Performed in-line its overall industry.

0A7L Stock Forecast FAQ

What is GB:0A7L’s average 12-month price target, according to analysts?

Based on analyst ratings, Irhythm Technologies’s 12-month average price target is 174.78.

What is GB:0A7L’s upside potential, based on the analysts’ average price target?

Irhythm Technologies has 55.51% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Irhythm Technologies a Buy, Sell or Hold?

Irhythm Technologies has a consensus rating of Strong Buy, which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.

What is Irhythm Technologies’s share price target?

The average share price target for Irhythm Technologies is 174.78. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $196.00 ,and the lowest forecast is $157.00. The average share price target represents 55.51% Increase from the current price of $112.39.

What do analysts say about Irhythm Technologies?

Irhythm Technologies’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of Irhythm Technologies?

To buy shares of GB:0A7L, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Irhythm Technologies (0A7L) Share Forecast & Price Target

0A7L Analyst Ratings

0A7L Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Irhythm Technologies

0A7L Analyst Recommendation Trends

0A7L Financial Forecast

0A7L Earnings Forecast

0A7L Sales Forecast

0A7L Stock Forecast FAQ

Detailed List of Analyst Forecasts